Table 2 |
||
|
Characteristics of the patients with polymyositis/dermatomyositis for muscle and lung analysis |
||
|
PM/DM patients (n = 11) |
||
|
|
||
|
Muscle (n = 5) |
Lung (n = 6) |
|
|
|
||
|
Number of PM/DM |
2/3 |
3/3 |
|
Number of males/females |
2/3 |
1/5 |
|
Age (years) |
60.4 ± 5.3 |
59.8 ± 4.3 |
|
Duration of the disease (month) |
17.6 ± 13.4 |
20.8 ± 13.2 |
|
Number of cases of new onset/flare |
4/1 |
3/3 |
|
Number of antinuclear antibody-positive |
1 (n = 4) |
1 (n = 5) |
|
Number of anti-Jo-1 antibody-positive |
0 (n = 4) |
1 (n = 5) |
|
Serum creatinine kinase (IU/l)a |
2,946.4 ± 1,195.4 |
141.4 ± 57.4 (n = 5) |
|
Manual muscle testing score |
54.3 ± 5.8 (n = 4) |
NA |
|
Number of patients with ILD |
4 |
6 |
|
AaDO2 with ILD |
NA |
22.7 ± 6.6 (n = 5) |
|
Treatment at time of biopsy |
||
|
Untreated |
4 |
4 |
|
Prednisolone alone |
0 |
2 |
|
Prednisolone and cyclosporine |
1 |
0 |
|
|
||
|
Data presented as n or mean ± standard error of the mean. Antinuclear antibody was analyzed by immunofluorescence assay. The titer of anti-Jo-1 antibody was investigated by enzyme immunoassay. Although in some patients, anti-dsDNA (n = 1 and n = 2 for muscle and lung samples, respectively), anti-RNP (n = 1 and n = 2), anti-Scl-70 (n = 1 and n = 2), and anti-SS-A (n = 1 and n = 4) antibodies and rheumatoid factor (n = 2 and n = 4) were analyzed, they were all negative. AaDO2, alveolar-arterial oxygen pressure difference; ILD, interstitial lung disease; NA, not available; PM/DM, polymyositis/dermatomyositis. aNormal range: male < 197 IU/l, female < 180 IU/l. |
||
|
Suzuki et al. Arthritis Research & Therapy 2012 14:R48 doi:10.1186/ar3761 |
||
